StockIQpro
NASDAQ:ORIC

Oric Pharmaceuticals, Inc.

Track all markets on TradingView
Track all markets on TradingView

Oric Pharmaceuticals, Inc. reported net income of −$129.5M in fiscal 2025. Free cash flow was −$111.7M, and the diluted share count rose 25.9%.Summary generated from Oric Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Feb 23, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−41.3%
Debt / equityn/a
Free cash flow−$111.7M
FCF marginn/a
Share count change+25.9%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−79−92−111−143−143
Net income−79−89−101−128−129
Free cash flow−60−77−87−114−112

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations